Forma Therapeutics Secures $25M in Private Funds to Buy Discovery Tools | GenomeWeb
Forma Therapeutics, a drug discovery company co-founded by scientists from the Broad Institute, this week emerged from stealth mode by announcing that it has secured $25 million in equity-backed and non-dilutive funding.
 
The company will use the financing to help it become what it calls an integrated drug discoverer that will use data from the National Institutes of Health’s Cancer Genome Atlas Project to seek out “challenging” drug targets, President and CEO Steven Tregay said this week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.